

Covid-19 Impact on Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C679AAEB69F8EN.html>

Date: June 2020

Pages: 92

Price: US\$ 3,900.00 (Single User License)

ID: C679AAEB69F8EN

Abstracts

CAR-T Therapy in Haematological Malignancy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global CAR-T Therapy in Haematological Malignancy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CAR-T Therapy in Haematological Malignancy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the CAR-T Therapy in Haematological Malignancy industry.

The key players covered in this study

Celgene (Juno Therapeutics)

Novartis

Gilead (Kite Pharma)

Pfizer

CARsgen Therapeutics

Autolus Therapeutics

Aurora BioPharma

Sorrento Therapeutics

Mustang Bio

Bluebird Bio

Collectis

Allogene Therapeutics

Celyad

Market segment by Type, the product can be split into

Allogeneic

Autologous

Market segment by Application, split into

Hospitals

Cancer Research Centers

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global CAR-T Therapy in Haematological Malignancy status, future forecast, growth opportunity, key market and key players.

To present the CAR-T Therapy in Haematological Malignancy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of CAR-T Therapy in Haematological Malignancy are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the

prior year has been considered.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
- 1.4 Covid-19 Implications on Market by Type
 - 1.4.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Allogeneic
 - 1.4.3 Autologous
- 1.5 Market by Application
 - 1.5.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026
 - 1.5.2 Hospitals
 - 1.5.3 Cancer Research Centers
 - 1.5.4 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): CAR-T Therapy in Haematological Malignancy Industry Impact
 - 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.6.2 Covid-19 Impact: Commodity Prices Indices
 - 1.6.3 Covid-19 Impact: Global Major Government Policy
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Market Perspective (2015-2026)
- 2.2 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Growth Trends by Regions
 - 2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Share by Regions (2015-2020)
 - 2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 CAR-T Therapy in Haematological Malignancy Market Growth Strategy

2.3.6 Primary Interviews with Key CAR-T Therapy in Haematological Malignancy Players (Opinion Leaders)

3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Market Size

3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2015-2020)

3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2015-2020)

3.1.3 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio

3.2.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2019

3.3 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served

3.4 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service

3.5 Date of Enter into CAR-T Therapy in Haematological Malignancy Market

3.6 Mergers & Acquisitions, Expansion Plans

4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)

4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2015-2020)

4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2021-2026)

5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)

5.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA IMPACT OF COVID-19

6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)

6.2 CAR-T Therapy in Haematological Malignancy Key Players in North America (2019-2020)

6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

7 EUROPE IMPACT OF COVID-19

7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)

7.2 CAR-T Therapy in Haematological Malignancy Key Players in Europe (2019-2020)

7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

8 CHINA IMPACT OF COVID-19

8.1 China CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)

8.2 CAR-T Therapy in Haematological Malignancy Key Players in China (2019-2020)

8.3 China CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

8.4 China CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

9 JAPAN IMPACT OF COVID-19

9.1 Japan CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)

9.2 CAR-T Therapy in Haematological Malignancy Key Players in Japan (2019-2020)

9.3 Japan CAR-T Therapy in Haematological Malignancy Market Size by Type

(2015-2020)

9.4 Japan CAR-T Therapy in Haematological Malignancy Market Size by Application
(2015-2020)

10 SOUTHEAST ASIA IMPACT OF COVID-19

10.1 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size
(2015-2020)

10.2 CAR-T Therapy in Haematological Malignancy Key Players in Southeast Asia
(2019-2020)

10.3 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by
Type (2015-2020)

10.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by
Application (2015-2020)

11 INDIA IMPACT OF COVID-19

11.1 India CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)

11.2 CAR-T Therapy in Haematological Malignancy Key Players in India (2019-2020)

11.3 India CAR-T Therapy in Haematological Malignancy Market Size by Type
(2015-2020)

11.4 India CAR-T Therapy in Haematological Malignancy Market Size by Application
(2015-2020)

12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19

12.1 Central & South America CAR-T Therapy in Haematological Malignancy Market
Size (2015-2020)

12.2 CAR-T Therapy in Haematological Malignancy Key Players in Central & South
America (2019-2020)

12.3 Central & South America CAR-T Therapy in Haematological Malignancy Market
Size by Type (2015-2020)

12.4 Central & South America CAR-T Therapy in Haematological Malignancy Market
Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Celgene (Juno Therapeutics)

13.1.1 Celgene (Juno Therapeutics) Company Details

- 13.1.2 Celgene (Juno Therapeutics) Business Overview and Its Total Revenue
- 13.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
- 13.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020))
- 13.1.5 Celgene (Juno Therapeutics) Recent Development and Reaction to COVID-19
- 13.2 Novartis
 - 13.2.1 Novartis Company Details
 - 13.2.2 Novartis Business Overview and Its Total Revenue
 - 13.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
 - 13.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
 - 13.2.5 Novartis Recent Development and Reaction to COVID-19
- 13.3 Gilead (Kite Pharma)
 - 13.3.1 Gilead (Kite Pharma) Company Details
 - 13.3.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
 - 13.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
 - 13.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
 - 13.3.5 Gilead (Kite Pharma) Recent Development and Reaction to COVID-19
- 13.4 Pfizer
 - 13.4.1 Pfizer Company Details
 - 13.4.2 Pfizer Business Overview and Its Total Revenue
 - 13.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
 - 13.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
 - 13.4.5 Pfizer Recent Development and Reaction to COVID-19
- 13.5 CARsgen Therapeutics
 - 13.5.1 CARsgen Therapeutics Company Details
 - 13.5.2 CARsgen Therapeutics Business Overview and Its Total Revenue
 - 13.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
 - 13.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
 - 13.5.5 CARsgen Therapeutics Recent Development and Reaction to COVID-19
- 13.6 Autolus Therapeutics
 - 13.6.1 Autolus Therapeutics Company Details
 - 13.6.2 Autolus Therapeutics Business Overview and Its Total Revenue

13.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy

Introduction

13.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

13.6.5 Autolus Therapeutics Recent Development and Reaction to COVID-19

13.7 Aurora BioPharma

13.7.1 Aurora BioPharma Company Details

13.7.2 Aurora BioPharma Business Overview and Its Total Revenue

13.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction

13.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

13.7.5 Aurora BioPharma Recent Development and Reaction to COVID-19

13.8 Sorrento Therapeutics

13.8.1 Sorrento Therapeutics Company Details

13.8.2 Sorrento Therapeutics Business Overview and Its Total Revenue

13.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction

13.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

13.8.5 Sorrento Therapeutics Recent Development and Reaction to COVID-19

13.9 Mustang Bio

13.9.1 Mustang Bio Company Details

13.9.2 Mustang Bio Business Overview and Its Total Revenue

13.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction

13.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

13.9.5 Mustang Bio Recent Development and Reaction to COVID-19

13.10 Bluebird Bio

13.10.1 Bluebird Bio Company Details

13.10.2 Bluebird Bio Business Overview and Its Total Revenue

13.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction

13.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

13.10.5 Bluebird Bio Recent Development and Reaction to COVID-19

13.11 Collectis

10.11.1 Collectis Company Details

10.11.2 Collectis Business Overview and Its Total Revenue

10.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction

10.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business

(2015-2020)

10.11.5 Collectis Recent Development and Reaction to COVID-19

13.12 Allogene Therapeutics

10.12.1 Allogene Therapeutics Company Details

10.12.2 Allogene Therapeutics Business Overview and Its Total Revenue

10.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy

Introduction

10.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

10.12.5 Allogene Therapeutics Recent Development and Reaction to COVID-19

13.13 Celyad

10.13.1 Celyad Company Details

10.13.2 Celyad Business Overview and Its Total Revenue

10.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction

10.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business

(2015-2020)

10.13.5 Celyad Recent Development and Reaction to COVID-19

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. CAR-T Therapy in Haematological Malignancy Key Market Segments
- Table 2. Key Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
- Table 3. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of Allogeneic
- Table 6. Key Players of Autologous
- Table 7. COVID-19 Impact Global Market: (Four CAR-T Therapy in Haematological Malignancy Market Size Forecast Scenarios)
- Table 8. Opportunities and Trends for CAR-T Therapy in Haematological Malignancy Players in the COVID-19 Landscape
- Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 10. Key Regions/Countries Measures against Covid-19 Impact
- Table 11. Proposal for CAR-T Therapy in Haematological Malignancy Players to Combat Covid-19 Impact
- Table 12. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 13. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 14. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020) (US\$ Million)
- Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2015-2020)
- Table 16. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 17. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2021-2026)
- Table 18. Market Top Trends
- Table 19. Key Drivers: Impact Analysis
- Table 20. Key Challenges
- Table 21. CAR-T Therapy in Haematological Malignancy Market Growth Strategy
- Table 22. Main Points Interviewed from Key CAR-T Therapy in Haematological Malignancy Players

Table 23. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2015-2020) (Million US\$)

Table 24. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2015-2020)

Table 25. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2019)

Table 26. Global CAR-T Therapy in Haematological Malignancy by Players Market Concentration Ratio (CR5 and HHI)

Table 27. Key Players Headquarters and Area Served

Table 28. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service

Table 29. Date of Enter into CAR-T Therapy in Haematological Malignancy Market

Table 30. Mergers & Acquisitions, Expansion Plans

Table 31. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 32. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Type (2015-2020)

Table 33. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2021-2026)

Table 34. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2015-2020)

Table 35. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 36. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2021-2026)

Table 37. North America Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 38. North America Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 39. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 40. North America CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 41. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 42. North America CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 43. Europe Key Players CAR-T Therapy in Haematological Malignancy Revenue

(2019-2020) (Million US\$)

Table 44. Europe Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 45. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 46. Europe CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 47. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 48. Europe CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 49. China Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 50. China Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 51. China CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 52. China CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 53. China CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 54. China CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 55. Japan Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 56. Japan Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 57. Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 58. Japan CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 59. Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 60. Japan CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 61. Southeast Asia Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 62. Southeast Asia Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 63. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 65. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 66. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 67. India Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 68. India Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 69. India CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 70. India CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 71. India CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 72. India CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 73. Central & South America Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US\$)

Table 74. Central & South America Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)

Table 75. Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US\$)

Table 76. Central & South America CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)

Table 77. Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US\$)

Table 78. Central & South America CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)

Table 79. Celgene (Juno Therapeutics) Company Details

Table 80. Celgene (Juno Therapeutics) Business Overview

Table 81. Celgene (Juno Therapeutics) Product

Table 82. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 83. Celgene (Juno Therapeutics) Recent Development

Table 84. Novartis Company Details

Table 85. Novartis Business Overview

Table 86. Novartis Product

Table 87. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 88. Novartis Recent Development

Table 89. Gilead (Kite Pharma) Company Details

Table 90. Gilead (Kite Pharma) Business Overview

Table 91. Gilead (Kite Pharma) Product

Table 92. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 93. Gilead (Kite Pharma) Recent Development

Table 94. Pfizer Company Details

Table 95. Pfizer Business Overview

Table 96. Pfizer Product

Table 97. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 98. Pfizer Recent Development

Table 99. CARsgen Therapeutics Company Details

Table 100. CARsgen Therapeutics Business Overview

Table 101. CARsgen Therapeutics Product

Table 102. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 103. CARsgen Therapeutics Recent Development

Table 104. Autolus Therapeutics Company Details

Table 105. Autolus Therapeutics Business Overview

Table 106. Autolus Therapeutics Product

Table 107. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 108. Autolus Therapeutics Recent Development

Table 109. Aurora BioPharma Company Details

Table 110. Aurora BioPharma Business Overview

Table 111. Aurora BioPharma Product

Table 112. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 113. Aurora BioPharma Recent Development

Table 114. Sorrento Therapeutics Business Overview

Table 115. Sorrento Therapeutics Product

Table 116. Sorrento Therapeutics Company Details

Table 117. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological

Malignancy Business (2015-2020) (Million US\$)

Table 118. Sorrento Therapeutics Recent Development

Table 119. Mustang Bio Company Details

Table 120. Mustang Bio Business Overview

Table 121. Mustang Bio Product

Table 122. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 123. Mustang Bio Recent Development

Table 124. Bluebird Bio Company Details

Table 125. Bluebird Bio Business Overview

Table 126. Bluebird Bio Product

Table 127. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 128. Bluebird Bio Recent Development

Table 129. Collectis Company Details

Table 130. Collectis Business Overview

Table 131. Collectis Product

Table 132. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 133. Collectis Recent Development

Table 134. Allogene Therapeutics Company Details

Table 135. Allogene Therapeutics Business Overview

Table 136. Allogene Therapeutics Product

Table 137. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 138. Allogene Therapeutics Recent Development

Table 139. Celyad Company Details

Table 140. Celyad Business Overview

Table 141. Celyad Product

Table 142. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US\$)

Table 143. Celyad Recent Development

Table 144. Research Programs/Design for This Report

Table 145. Key Data Information from Secondary Sources

Table 146. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2020 VS 2026

Figure 2. Allogeneic Features

Figure 3. Autologous Features

Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026

Figure 5. Hospitals Case Studies

Figure 6. Cancer Research Centers Case Studies

Figure 7. Others Case Studies

Figure 8. CAR-T Therapy in Haematological Malignancy Report Years Considered

Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 10. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2020 VS 2026

Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2021-2026)

Figure 12. Porter's Five Forces Analysis

Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2019

Figure 14. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2019)

Figure 15. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2019

Figure 16. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 17. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 18. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. India CAR-T Therapy in Haematological Malignancy Market Size YoY

Growth (2015-2020) (Million US\$)

Figure 22. Central & South America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US\$)

Figure 23. Celgene (Juno Therapeutics) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 24. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 25. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 26. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 27. Gilead (Kite Pharma) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 29. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 31. CARsgen Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 33. Autolus Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 35. Aurora BioPharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 37. Sorrento Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 39. Mustang Bio Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 41. Bluebird Bio Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 43. Collectis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 45. Allogene Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 47. Celyad Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)

Figure 49. Bottom-up and Top-down Approaches for This Report

Figure 50. Data Triangulation

Figure 51. Key Executives Interviewed

I would like to order

Product name: Covid-19 Impact on Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C679AAEB69F8EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C679AAEB69F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

